P783: SYSTEMIC THERAPY UTILIZATION AND HEMATOLOGIC OUTCOMES IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FINDINGS FROM A REAL-WORLD MEDICAL RECORD REVIEW STUDY IN THE US, UK, AND EUROPE (EU)

Схожие документы

• S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
  по: Matteo Giovanni Della Porta, и др.
  Опубликовано: (2023-08-01)
• EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
  по: G. Garcia-Manero, и др.
  Опубликовано: (2024-01-01)
• Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
  по: Angela Consagra, и др.
  Опубликовано: (2025-02-01)
• B04 | OVERALL SURVIVAL AND DURATION OF TRANSFUSION INDEPENDENCE FOR FIRST-LINE ERYTHROPOIESIS STIMULATING AGENT-NAIVE PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH LUSPATERCEPT VS. EPOETIN ALFA: COMMANDS TRIAL
  по: V. Santini, и др.
  Опубликовано: (2025-09-01)
• Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS
  по: Rami S. Komrokji, и др.
  Опубликовано: (2025-12-01)